316 related articles for article (PubMed ID: 20479064)
1. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells.
Vonderheide RH; LoRusso PM; Khalil M; Gartner EM; Khaira D; Soulieres D; Dorazio P; Trosko JA; Rüter J; Mariani GL; Usari T; Domchek SM
Clin Cancer Res; 2010 Jul; 16(13):3485-94. PubMed ID: 20479064
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma.
Rini BI; Stein M; Shannon P; Eddy S; Tyler A; Stephenson JJ; Catlett L; Huang B; Healey D; Gordon M
Cancer; 2011 Feb; 117(4):758-67. PubMed ID: 20922784
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours.
Millward M; Underhill C; Lobb S; McBurnie J; Meech SJ; Gomez-Navarro J; Marshall MA; Huang B; Mather CB
Br J Cancer; 2013 May; 108(10):1998-2004. PubMed ID: 23652314
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.
Krop IE; Beeram M; Modi S; Jones SF; Holden SN; Yu W; Girish S; Tibbitts J; Yi JH; Sliwkowski MX; Jacobson F; Lutzker SG; Burris HA
J Clin Oncol; 2010 Jun; 28(16):2698-704. PubMed ID: 20421541
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer.
Chung KY; Gore I; Fong L; Venook A; Beck SB; Dorazio P; Criscitiello PJ; Healey DI; Huang B; Gomez-Navarro J; Saltz LB
J Clin Oncol; 2010 Jul; 28(21):3485-90. PubMed ID: 20498386
[TBL] [Abstract][Full Text] [Related]
6. Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma.
Ralph C; Elkord E; Burt DJ; O'Dwyer JF; Austin EB; Stern PL; Hawkins RE; Thistlethwaite FC
Clin Cancer Res; 2010 Mar; 16(5):1662-72. PubMed ID: 20179239
[TBL] [Abstract][Full Text] [Related]
7. A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer.
Aglietta M; Barone C; Sawyer MB; Moore MJ; Miller WH; Bagalà C; Colombi F; Cagnazzo C; Gioeni L; Wang E; Huang B; Fly KD; Leone F
Ann Oncol; 2014 Sep; 25(9):1750-1755. PubMed ID: 24907635
[TBL] [Abstract][Full Text] [Related]
8. Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer.
Kwa M; Li X; Novik Y; Oratz R; Jhaveri K; Wu J; Gu P; Meyers M; Muggia F; Speyer J; Iwano A; Bonakdar M; Kozhaya L; Tavukcuoglu E; Budan B; Raad R; Goldberg JD; Unutmaz D; Adams S
Breast Cancer Res Treat; 2018 Feb; 168(1):57-67. PubMed ID: 29124456
[TBL] [Abstract][Full Text] [Related]
9. Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab?
Ménard C; Ghiringhelli F; Roux S; Chaput N; Mateus C; Grohmann U; Caillat-Zucman S; Zitvogel L; Robert C
Clin Cancer Res; 2008 Aug; 14(16):5242-9. PubMed ID: 18698043
[TBL] [Abstract][Full Text] [Related]
10. Treatment of advanced hormone-sensitive breast cancer in postmenopausal women with exemestane alone or in combination with celecoxib.
Dirix LY; Ignacio J; Nag S; Bapsy P; Gomez H; Raghunadharao D; Paridaens R; Jones S; Falcon S; Carpentieri M; Abbattista A; Lobelle JP
J Clin Oncol; 2008 Mar; 26(8):1253-9. PubMed ID: 18323548
[TBL] [Abstract][Full Text] [Related]
11. Pilot study evaluating the pharmacokinetics, pharmacodynamics, and safety of the combination of exemestane and tamoxifen.
Rivera E; Valero V; Francis D; Asnis AG; Schaaf LJ; Duncan B; Hortobagyi GN
Clin Cancer Res; 2004 Mar; 10(6):1943-8. PubMed ID: 15041710
[TBL] [Abstract][Full Text] [Related]
12. Effects of double blockade of CD28 and inducible-costimulator signaling on anti-glomerular basement membrane glomerulonephritis.
Okano K; Nitta K; Ogawa S; Horita S; Habiro K; Nihei H; Abe R
J Lab Clin Med; 2004 Oct; 144(4):183-92. PubMed ID: 15514586
[TBL] [Abstract][Full Text] [Related]
13. Synergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo.
Suarez N; Alfaro C; Dubrot J; Palazon A; Bolaños E; Erro L; Hervas-Stubbs S; Martinez-Forero I; Morales-Kastresana A; Martin-Algarra S; Sangro B; Lecanda F; Perez-Gracia JL; Gonzalez A; Melero I
Int J Cancer; 2011 Jul; 129(2):374-86. PubMed ID: 20853321
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma.
Ribas A; Comin-Anduix B; Chmielowski B; Jalil J; de la Rocha P; McCannel TA; Ochoa MT; Seja E; Villanueva A; Oseguera DK; Straatsma BR; Cochran AJ; Glaspy JA; Hui L; Marincola FM; Wang E; Economou JS; Gomez-Navarro J
Clin Cancer Res; 2009 Oct; 15(19):6267-76. PubMed ID: 19789309
[TBL] [Abstract][Full Text] [Related]
15. Effects of exemestane and tamoxifen in a postmenopausal breast cancer model.
Jelovac D; Macedo L; Handratta V; Long BJ; Goloubeva OG; Ingle JN; Brodie AM
Clin Cancer Res; 2004 Nov; 10(21):7375-81. PubMed ID: 15534114
[TBL] [Abstract][Full Text] [Related]
16. Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting.
Generali D; Montemurro F; Bordonaro R; Mafodda A; Romito S; Michelotti A; Piovano P; Ionta MT; Bighin C; Sartori D; Frassoldati A; Cazzaniga ME; Riccardi F; Testore F; Vici P; Barone CA; Schirone A; Piacentini F; Nolè F; Molino A; Latini L; Simoncini EL; Roila F; Cognetti F; Nuzzo F; Foglietta J; Minisini AM; Goffredo F; Portera G; Ascione G; Mariani G
Oncologist; 2017 Jun; 22(6):648-654. PubMed ID: 28432226
[TBL] [Abstract][Full Text] [Related]
17. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206).
Ribas A
Oncologist; 2008; 13 Suppl 4():10-5. PubMed ID: 19001146
[TBL] [Abstract][Full Text] [Related]
18. [Everolimus plus Exemestane in Postmenopausal Metastatic Breast Cancer Patients].
Yamamoto D; Tsubota Y; Sueoka N; Yamamoto C; Kon M
Gan To Kagaku Ryoho; 2015 Oct; 42(10):1319-21. PubMed ID: 26489585
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma.
Kirkwood JM; Lorigan P; Hersey P; Hauschild A; Robert C; McDermott D; Marshall MA; Gomez-Navarro J; Liang JQ; Bulanhagui CA
Clin Cancer Res; 2010 Feb; 16(3):1042-8. PubMed ID: 20086001
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of exemestane in combination with fulvestrant in postmenopausal women with advanced, hormone-responsive breast cancer.
Mrózek E; Layman R; Ramaswamy B; Schaaf L; Li X; Ottman S; Shapiro CL
Clin Breast Cancer; 2012 Apr; 12(2):151-6. PubMed ID: 22444722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
